Quick Answer
Biohaven Ltd. reported Operating Income Loss of -$745.38 million for the year ending 2025.
- Biohaven Ltd. showed an increase of +15.8% in Operating Income Loss from 2024 to 2025.
- This data is from Biohaven Ltd.'s annual report (Form 10-K), filed with the SEC on March 2, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2021: -$55.49 million | Q1 2022: -$89.77 million | Q2 2022: -$197.11 million | Q3 2022: -$67.64 million | Q1 2023: -$77.78 million | Q2 2023: -$94.01 million | Q3 2023: -$110.55 million | Q1 2024: -$183.24 million | Q2 2024: -$333.77 million | Q3 2024: -$178.17 million | Q1 2025: -$221.56 million | Q2 2025: -$211.70 million | Q3 2025: -$169.38 million.
- Over the full 6 years of available data (2020 to 2025), Biohaven Ltd.'s Operating Income Loss has declined by 551.0%.
- Historical annual values: Fiscal year 2025: -$745.38 million | Fiscal year 2024: -$885.11 million | Fiscal year 2023: -$436.05 million | Fiscal year 2022: -$567.93 million | Fiscal year 2021: -$218.90 million | Fiscal year 2020: -$114.51 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: